



Submitted by:  
Stephen J. Noga, MD, Ph.D.  
Vice President, U.S. Medical Affairs - Oncology  
Takeda Oncology  
40 Landsdowne Street  
Cambridge, MA 02139  
direct: 617.551.3693  
mobile: 410.419.7359  
Email: [stephen.noga@takeda.com](mailto:stephen.noga@takeda.com)

**Date of request: April 23, 2018**  
**NCCN Guidelines Panel: Multiple Myeloma**

On behalf of Takeda Pharmaceutical Company Limited, we respectfully request the NCCN Multiple Myeloma Panel to review the enclosed data on the use of single-agent ixazomib (NINLARO) as maintenance therapy for transplant-ineligible patients with multiple myeloma. We would also like to request review of the enclosed data on ixazomib in combination with lenalidomide as maintenance therapy for patients with newly diagnosed multiple myeloma who have received induction therapy followed by an autologous stem cell transplant.

**Specific Changes:**

- Recommend inclusion of ixazomib as a suggested Category 2A Preferred Regimen for Maintenance Therapy
- Recommend inclusion of ixazomib plus lenalidomide as a suggested Category 2A Preferred Regimen for Maintenance Therapy

**FDA Clearance:** Ixazomib in combination with lenalidomide and dexamethasone is approved by the US FDA for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is not currently approved by the US FDA as a maintenance therapy.

**Rationale:** An integrated analysis of long-term ixazomib maintenance therapy in four phase 1/2 studies in patients with newly diagnosed multiple myeloma not undergoing transplant (n=121) as well as updated data from the randomized phase 2 (NCT01718743) clinical trial of weekly ixazomib plus lenalidomide in patients with newly diagnosed multiple myeloma as maintenance therapy post-autologous stem cell transplant were presented at the 2017 Annual Meeting of the American Society of Hematology (ASH), suggesting activity and safety of ixazomib in the maintenance setting.

The following enclosures are submitted in support of the above proposed changes. We would like to acknowledge the contributions of NCCN panel members who are also co-authors of some of these publications.

- Dimopoulos MA, et al. Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. Blood 2017;130(Suppl 1):abstract 902; data from oral presentation at the 2017 Annual Meeting of ASH.



- Patel KK, et al. Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 2017;130(Suppl 1):abstract 437; data from oral presentation at the 2017 Annual Meeting of ASH.

Yours sincerely,

A handwritten signature in blue ink, appearing to read "Stephen J. Noga".

Stephen J. Noga, MD, Ph.D.  
Vice President, U.S. Medical Affairs - Oncology